Pharming Group’s Post

New installment in the A&R Immunology for the Rheumatologist series explores Sjögren disease endotyping to enhance patient stratification and clinical decision-making, and reviews emerging B cell-targeted therapies grounded in disease immunopathology Read the review in Arthritis & Rheumatology https://lnkd.in/eNuqaAm2

Big news in immunology today: The FDA has approved TREMFYA® (guselkumab) for pediatric patients aged ≥6 years (≥40 kg) with moderate to severe plaque psoriasis, as well as those with active psoriatic arthritis. Congratulations to the Johnson & Johnson immunology team on this milestone that represents the first selective IL-23 inhibitor approved for children with these chronic conditions. This is such an important advance in broadening treatment options for a population with limited choices. Why it matters: - Pediatric patients often face delayed diagnoses and fewer therapeutic options compared to adults. - Early intervention in immune-mediated diseases can help reshape long-term outcomes. - Expanding biologic therapies into younger populations highlights the growing recognition of the need for age-appropriate, evidence-based care. This not only transform clinical practice but brings new hope to families navigating these complex conditions. Congratulations for this significant step forward in advancing care for children living with chronic immune diseases.

New installment in the A&R Immunology for the Rheumatologist series takes an in-depth look at the crucial role of IL-5 in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) Read the review in Arthritis & Rheumatology https://lnkd.in/eTVBbG8s

LucidQuest YouTube > Trending in Immunology: Etrasimod, FDA Approvals, Cemiplimab and More: In this edition of Immunology Updates, we cover key developments in the field. Everest Medicines' Phase III trial shows promising results for etrasimod in ulcerative colitis. The FDA has approved upadacitinib as a first-line treatment for IBD and expanded SIMPONI®'s indication for pediatric UC. Regeneron’s cemiplimab gains FDA approval for high-risk CSCC, with EU approval pending. Replimune’s RP1 BLA resubmission for advanced melanoma is accepted, and Roche's Gazyva®/Gazyvaro® is approved for lupus nephritis, offering improved disease control and a convenient dosing regimen. http://dlvr.it/TNqCPB Subscribe for more! #LucidQuest #PharmaCI

LucidQuest YouTube > Trending in Immunology: Etrasimod, FDA Approvals, Cemiplimab and More: In this edition of Immunology Updates, we cover key developments in the field. Everest Medicines' Phase III trial shows promising results for etrasimod in ulcerative colitis. The FDA has approved upadacitinib as a first-line treatment for IBD and expanded SIMPONI®'s indication for pediatric UC. Regeneron’s cemiplimab gains FDA approval for high-risk CSCC, with EU approval pending. Replimune’s RP1 BLA resubmission for advanced melanoma is accepted, and Roche's Gazyva®/Gazyvaro® is approved for lupus nephritis, offering improved disease control and a convenient dosing regimen. http://dlvr.it/TNqCNl Subscribe for more! #LucidQuest #PharmaCI

Sponsored Content At Anaptys, we are focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our lead program, rosnilimab, is designed to selectively and potently deplete pathogenic T cells and is currently being studied in a Phase 2 trial for the treatment of #ulcerativecolitis (NCT06127043). Top-line results are anticipated in Q4 2025. If you are on site at UEG Week, please visit the moderated poster session from 1-2 PM CEST and e-posters on October 6 for rosnilimab presentations (MP470 & PP0358). Read more about our publications at http://bit.ly/4kXRT3F

🧒 Tackling Viral Infections After Transplant in Children | Pediatric Track Highlights from Tandem 2025 Viral infections remain one of the most persistent challenges in pediatric transplant care — and the 2025 Tandem Meetings shed new light on both progress and setbacks in this field. On February 12, the session “Cells or Drugs: The Future of Antiviral Therapy in Transplant” brought together leading experts to discuss the latest data on antiviral therapies and immune-based strategies. 💬 Dr. Caitlin Elgarten (Children’s Hospital of Philadelphia) chaired the panel, emphasizing the importance of balanced updates on prevention and treatment. 🧬 Dr. Michael Keller (Children’s National Hospital) discussed the mixed results from recent trials on virus-specific T-cells, highlighting the need to refine patient selection and therapeutic contexts. 💊 Dr. Michael Boeckh (Fred Hutchinson Cancer Center) explored the evolving antiviral drug landscape, including the recent FDA approval of letermovir for CMV prophylaxis in children aged six months and older. Despite ongoing challenges, the field continues to advance toward safer, more effective viral management strategies for pediatric transplant recipients. 📺 This session is available on-demand for registered attendees of the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®. 🔗 Read more on our LinkedIn page to stay updated on the latest in transplant and cellular therapy research. https://lnkd.in/gp2BngAw #PediatricTransplant #AntiviralTherapy #CellularTherapy #Tandem2025 #ASTCT #CIBMTR #MediaMedic

Proud to share that MaaT013 (Xervyteg®) clinical data were featured in the latest special issue on acute Graft-versus-Host Disease (aGvHD) in Current Opinion in Immunology. The review article, titled “Emerging novel therapies for steroid-refractory acute graft-versus-host disease: recent advances and future directions,” highlights therapeutic innovations addressing urgent unmet needs in steroid- and ruxolitinib-refractory aGvHD. We are honored that MaaT013, our lead drug candidate, is recognized among the promising new approaches. The inclusion of data from our HERACLES Phase 2 trial and compassionate use program underscores the growing body of clinical evidence supporting microbiotherapy in improving outcomes for patients with aGvHD. 👏 Our thanks and congratulations to authors Yishan Ye, Wenjing Hao, Florent Malard, and Mohamad Mohty for this comprehensive and insightful review. 🔗 Read the full open-access article here: https://lnkd.in/eZTDf6wC #Microbiome #aGvHD #AlloHCT #Innovation #ClinicalResearch #Immunology #GutMicrobiome #Hematology #HemOnc #Microbiota

The Crohn’s & Colitis Foundation is hosting its second meeting today focused on IBD prevention, a key focus of our research agenda. We’ve brought together global experts in IBD, immunology, and vaccinology to explore the development of innovative therapeutic interventions aimed at intercepting and preventing Crohn’s disease and ulcerative colitis.

Excited to share that Biogen has licensed Vanqua Bio’s oral C5aR1 antagonist, expanding our immunology & inflammation pipeline and deepening our exploration of complement biology in immune-mediated diseases.